JP5492564B2 - ビスホスホネートの水性懸濁液を含む長期徐放性医薬組成物 - Google Patents

ビスホスホネートの水性懸濁液を含む長期徐放性医薬組成物 Download PDF

Info

Publication number
JP5492564B2
JP5492564B2 JP2009542815A JP2009542815A JP5492564B2 JP 5492564 B2 JP5492564 B2 JP 5492564B2 JP 2009542815 A JP2009542815 A JP 2009542815A JP 2009542815 A JP2009542815 A JP 2009542815A JP 5492564 B2 JP5492564 B2 JP 5492564B2
Authority
JP
Japan
Prior art keywords
salt
pharmaceutical composition
calcium
acid
aqueous suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009542815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513483A5 (enExample
JP2010513483A (ja
Inventor
ヨンフェン チャン，ジャック
ツィピン ルオ，メアリー
フェイ，ディンギュアン
シエ，ケビン
フェイ ディン，ジェ
Original Assignee
アムファスター ファーマシューティカルズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムファスター ファーマシューティカルズ，インコーポレイティド filed Critical アムファスター ファーマシューティカルズ，インコーポレイティド
Publication of JP2010513483A publication Critical patent/JP2010513483A/ja
Publication of JP2010513483A5 publication Critical patent/JP2010513483A5/ja
Application granted granted Critical
Publication of JP5492564B2 publication Critical patent/JP5492564B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2009542815A 2006-12-21 2007-12-13 ビスホスホネートの水性懸濁液を含む長期徐放性医薬組成物 Expired - Fee Related JP5492564B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87680006P 2006-12-21 2006-12-21
US60/876,800 2006-12-21
US11/768,181 2007-06-25
US11/768,181 US8974801B2 (en) 2006-12-21 2007-06-25 Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
PCT/US2007/025569 WO2008085281A1 (en) 2006-12-21 2007-12-13 Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate

Publications (3)

Publication Number Publication Date
JP2010513483A JP2010513483A (ja) 2010-04-30
JP2010513483A5 JP2010513483A5 (enExample) 2011-06-23
JP5492564B2 true JP5492564B2 (ja) 2014-05-14

Family

ID=39543732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009542815A Expired - Fee Related JP5492564B2 (ja) 2006-12-21 2007-12-13 ビスホスホネートの水性懸濁液を含む長期徐放性医薬組成物

Country Status (14)

Country Link
US (3) US8974801B2 (enExample)
EP (2) EP2548441B1 (enExample)
JP (1) JP5492564B2 (enExample)
CN (1) CN101616591B (enExample)
BR (1) BRPI0720605A2 (enExample)
CA (1) CA2673058C (enExample)
DK (2) DK2120585T3 (enExample)
ES (2) ES2396733T3 (enExample)
MX (1) MX2009006447A (enExample)
PL (2) PL2548441T3 (enExample)
PT (2) PT2120585E (enExample)
RU (1) RU2453316C2 (enExample)
SI (1) SI2120585T1 (enExample)
WO (1) WO2008085281A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101813728B1 (ko) * 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
AU2010330909B2 (en) 2009-12-18 2014-09-11 Howmedica Osteonics Corp. Post irradiation shelf-stable dual paste direct injectable bone cement precursor systems and methods of making same
CN102453050B (zh) * 2010-11-03 2015-01-07 成都云克药业有限责任公司 一种二膦酸化合物及其制备方法
ES2714701T3 (es) 2010-11-10 2019-05-29 Stryker European Holdings I Llc Proceso para la preparación de una espuma ósea polimérica
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2013175385A1 (en) 2012-05-20 2013-11-28 Bar-Ilan Research And Development Company Ltd. Bisphosphonates vinylic monomers and polymers and uses thereof
US9492268B2 (en) 2012-11-13 2016-11-15 The Secant Group, Llc Tapered tubular implant formed from woven fabric
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
CN108815117A (zh) * 2018-08-23 2018-11-16 宁波蒙曼生物科技有限公司 一种镇痛药物组合物及其制备方法
CN109930209B (zh) * 2019-03-07 2022-02-15 华南理工大学 一种具高结晶度及长径比双膦酸盐晶体及其制备方法
CN112707934A (zh) * 2020-12-30 2021-04-27 华南理工大学 一种阿仑膦酸钙配合物及其制备方法
CN114349786B (zh) * 2021-12-28 2023-07-11 中国科学院上海硅酸盐研究所 阿仑膦酸钙超长纳米线及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356887A (en) 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
WO1995008304A1 (en) * 1993-09-21 1995-03-30 The Penn State Research Foundation Bone substitute composition comprising hydroxyapatite and a method of production therefor
US5462932A (en) 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
EP1028712B1 (en) 1997-09-19 2005-01-12 Shire Laboratories Inc. Solid solution beadlet
SE9703691D0 (sv) 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
WO1999067809A1 (en) 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
KR100492110B1 (ko) * 2000-05-05 2005-06-02 에프. 호프만-라 로슈 아게 비스포스폰산 또는 그의 염을 포함하는 피하 투여용겔-유사 약학 조성물
US6350471B1 (en) 2000-05-31 2002-02-26 Pharma Pass Llc Tablet comprising a delayed release coating
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
JP4161031B2 (ja) 2000-10-31 2008-10-08 独立行政法人産業技術総合研究所 亜鉛含有リン酸カルシウム微粒子含有懸濁液または粒子溶媒混合系及び亜鉛欠乏症治療剤
GB0029111D0 (en) 2000-11-29 2001-01-10 Novartis Ag Organic compounds
US6558702B2 (en) 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
FR2836681B1 (fr) 2002-03-04 2004-06-18 Centre Nat Rech Scient Compose phosphocalcique modifie, composition injectable le contenant
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
JP2007501241A (ja) 2003-08-06 2007-01-25 ローディア インコーポレイティド 骨成長を促進する方法
US7420000B2 (en) 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
US20050261250A1 (en) 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation

Also Published As

Publication number Publication date
EP2120585A4 (en) 2011-11-23
PL2120585T3 (pl) 2013-03-29
PT2120585E (pt) 2013-01-15
US20150157650A1 (en) 2015-06-11
PL2548441T3 (pl) 2015-02-27
EP2548441B1 (en) 2014-08-27
PT2548441E (pt) 2014-11-27
EP2120585A1 (en) 2009-11-25
RU2009128023A (ru) 2011-01-27
EP2120585B1 (en) 2012-10-03
CA2673058A1 (en) 2008-07-17
ES2524690T3 (es) 2014-12-11
BRPI0720605A2 (pt) 2014-04-08
US8974801B2 (en) 2015-03-10
SI2120585T1 (sl) 2013-05-31
RU2453316C2 (ru) 2012-06-20
CN101616591B (zh) 2014-06-18
CN101616591A (zh) 2009-12-30
US20080153784A1 (en) 2008-06-26
DK2548441T3 (en) 2014-12-08
MX2009006447A (es) 2009-07-27
US20150157649A1 (en) 2015-06-11
WO2008085281A1 (en) 2008-07-17
DK2120585T3 (da) 2013-01-21
CA2673058C (en) 2015-11-24
EP2548441A1 (en) 2013-01-23
ES2396733T3 (es) 2013-02-25
JP2010513483A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
JP2010513483A (ja) ビスホスホネートの水性懸濁液を含む長期徐放性医薬組成物
RU2465922C2 (ru) Инъецируемый кальций-фосфатный цемент в форме апатита, высвобождающий ингибитор резорбции костной ткани
JP2010513483A5 (enExample)
US5356887A (en) Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
EP0449405B1 (en) Use of bisphosphonic acids for the treatment of calcium metabolism disorders
Brown et al. Developments in the therapeutic applications of bisphosphonates
KR100385697B1 (ko) 올파드로네이트를포함하는골체량동화성조성물
JP2002526412A (ja) 跛行を処置するための医薬品製剤の製造におけるビスホスホン酸誘導体の使用
Bixofis et al. Implications of the use of bisphosphonates in dental treatment-experience of the service of oral and maxillofacial surgery, Erasto Gaertner Hospital, Curitiba, Brazil
Ramesh et al. Bisphosphonates-what’s new
AU2008214596B2 (en) Injectable calcium-phosphate cement releasing a bone resorption inhibitor
WO2026058954A1 (ja) ポリリン酸カルシウムを含む固形粒子を含む分散製剤
JP2002332235A (ja) 骨疾患治療用液体医薬組成物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130311

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140303

R150 Certificate of patent or registration of utility model

Ref document number: 5492564

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees